Baird raised the firm’s price target on Crispr Therapeutics to $52 from $46 and keeps a Neutral rating on the shares. The firm said they announced 1Q24 results and provided pipeline updates, which they saw as generally in line with expectations, as the Casgevy launch gets off the ground and pipeline progresses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Crispr Therapeutics management to meet with Mizuho
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
- CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
- Crispr Therapeutics call volume above normal and directionally bullish